Atrion Corporation (ATRI) | Investment Case

1. Company Snapshot

1.a. Company Description

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally.Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.

Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults.The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment.In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications.

The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors.Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Show Full description

1.b. Last Insights on ATRI

Atrion Corporation's recent business developments have been driven by its proposed merger with Nordson Corporation for $460.00 per share in cash. The company's Q2 earnings were impacted by merger-related expenses, resulting in a significant year-over-year decline in EPS to $0.23. Despite this, revenue growth in the Medical Products and Services (MPS) and fluid delivery segments was strong. The merger is currently under investigation by law firms, including Halper Sadeh LLC and Monteverde & Associates PC, for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.

1.c. Company Highlights

Last Price	459.92
Change Percentage	0.06%
Open	459.75
Previous Close	459.66
Market Cap ( Millions)	809
Volume	29517
Year High	503.24
Year Low	274.98
M A 50	455.95
M A 200	400.15

FCF Yield	-0.29%
Dividend Yield	0.00%
ROE	8.05%
Debt / Equity	0.10%
Net Debt / EBIDTA	-8.83%
Price To Book	3.33
Price Earnings Ratio	41.72
Price To FCF	-349.95
Price To sales	4.78
EV / EBITDA	21.4

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

ATRI WELCOMES TWO INDUSTRY LEADERS TO ITS BOARD OF DIRECTORS

Nov -04

Source: prnewswire.com

Smaller But Mighty: 3 Small-Cap Stocks for Long-Term Dividend Growth

Aug -14

Source: investorplace.com

Atrion's (ATRI) Q2 Earnings Plummet Y/Y on Nordson Merger Costs

Aug -09

Source: zacks.com

Atrion Reports Second Quarter 2024 Results

Aug -08

Source: globenewswire.com

ATRI ALERT: The M&A Class Action Firm Investigates the Merger and August 19, 2024 Shareholder Vote of Atrion Corporation

Jul -29

Source: prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

Jul -28

Source: accesswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGR, SHCR on Behalf of Shareholders

Jul -17

Source: globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. – SILK

Jul -16

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.09%)

6. Segments

Fluid Delivery

Expected Growth: 4.8%

The fluid delivery market is driven by the increasing demand for IV systems, advancements in medical technology, and the growing need for efficient fluid delivery systems in hospitals and clinics.

Cardiovascular

Expected Growth: 7.8%

Growing demand for minimally invasive procedures, increasing prevalence of cardiovascular diseases, and advancements in medical technology drive the growth of Atrion's Cardiovascular segment.

Other

Expected Growth: 4.5%

Atrion's 'Other' segment, comprising minority interest in a joint venture and miscellaneous investments, is expected to grow steadily driven by increasing demand for diversified investments and strategic partnerships.

Ophthalmology

Expected Growth: 6.5%

Increasing prevalence of eye disorders, advancements in ophthalmic technologies, and growing demand for minimally invasive surgeries drive the ophthalmology market growth.

7. Detailed Products

Network Infrastructure Solutions

Atrion Corporation provides network infrastructure solutions that enable organizations to design, implement, and manage their network infrastructure efficiently.

Cybersecurity Services

Atrion Corporation offers cybersecurity services that help organizations protect themselves from cyber threats and vulnerabilities.

Unified Communications Solutions

Atrion Corporation provides unified communications solutions that enable organizations to collaborate and communicate effectively.

Cloud and Managed Services

Atrion Corporation offers cloud and managed services that help organizations migrate and manage their IT infrastructure in the cloud.

IT Consulting Services

Atrion Corporation provides IT consulting services that help organizations assess, design, and implement IT solutions that meet their business needs.

8. Atrion Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Atrion Corporation faces moderate threat from substitutes due to the availability of alternative products in the market.

Bargaining Power Of Customers

Atrion Corporation has a diverse customer base, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

Atrion Corporation relies on a few key suppliers, which gives them significant bargaining power.

Threat Of New Entrants

Atrion Corporation operates in a capital-intensive industry, which creates a barrier to entry for new entrants.

Intensity Of Rivalry

Atrion Corporation operates in a highly competitive industry, which leads to intense rivalry among existing players.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	0.10%
Debt Cost	7.06%
Equity Weight	99.90%
Equity Cost	7.06%
WACC	7.06%
Leverage	0.10%

11. Quality Control: Atrion Corporation passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Inefficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

InfuSystem Holdings

A-Score: 4.6/10

Value: 4.6

Growth: 5.7

Quality: 5.7

Yield: 0.0

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

Atrion

A-Score: 3.5/10

Value: 3.5

Growth: 3.0

Quality: 6.2

Yield: 1.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

NEXGEL

A-Score: 3.3/10

Value: 7.4

Growth: 4.9

Quality: 4.2

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

STAAR Surgical

A-Score: 3.2/10

Value: 8.0

Growth: 4.1

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

Femasys

A-Score: 2.7/10

Value: 6.0

Growth: 2.8

Quality: 3.1

Yield: 0.0

Momentum: 4.0

Volatility: 0.3

1-Year Total Return ->

Harvard Bioscience

A-Score: 2.2/10

Value: 9.2

Growth: 1.1

Quality: 2.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

16.52%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.06%

Atrion Corporation - US0499041053

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ATRI

1.c. Company Highlights

Expensive

Higher Yield

Better Quality

Average Quality

Average Yield

Medium Volatility

Less Volatile

Strong Momentum

Average Growth

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.09%)

6. Segments

Fluid Delivery

Expected Growth: 4.8%

Cardiovascular

Expected Growth: 7.8%

Other

Expected Growth: 4.5%

Ophthalmology

Expected Growth: 6.5%

7. Detailed Products

Network Infrastructure Solutions

Cybersecurity Services

Unified Communications Solutions

Cloud and Managed Services

IT Consulting Services

8. Atrion Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Atrion Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

459.92$

Current Price

459.92$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA